Nebraska Prior Authorization Transparency Act

Overview

Nebraska Legislative Bill 77 (LB 77), officially known as the “Ensuring Transparency in Prior Authorization Act,” represents a significant legislative effort to reform the prior authorization processes within health insurance and Medicaid systems across the state. This landmark legislation, signed into law by Governor Jim Pillen on June 4, 2025, aims to enhance transparency, streamline administrative procedures, and increase accountability for utilization review agents. A core component of LB 77 is its explicit address of artificial intelligence (AI) in healthcare decision-making, notably prohibiting the use of AI as the sole basis for denying, delaying, or modifying healthcare services. This provision underscores a growing concern regarding the ethical and practical implications of automated systems in critical patient care decisions, ensuring that human clinical judgment remains paramount in adverse determinations. The Act also extends its scope to include vital provisions for insurance and Medicaid coverage of biomarker testing, further broadening its impact on patient access to advanced diagnostic and personalized treatment options.

The impetus behind LB 77 stems from widespread frustrations among healthcare providers and patients regarding the often-opaque and burdensome prior authorization requirements that can delay or prevent necessary medical care. By introducing standardized forms, clear review timelines, and stringent disclosure requirements, the Act seeks to alleviate administrative burdens, minimize confusion, and improve overall efficiency in the healthcare system. The Nebraska Department of Insurance (NDOI) plays a crucial role in the implementation and oversight of these reforms, including the development and release of new standardized prior authorization forms that became effective January 1, 2026, for all fully insured plans in Nebraska. The legislation reflects a collaborative effort between the Nebraska Medical Association, Nebraska Hospital Association, and Blue Cross and Blue Shield of Nebraska, highlighting a consensus-driven approach to addressing long-standing challenges in healthcare access and delivery.

Definitions

While LB 77 itself provides specific definitions within its legislative text, the broader context of the “Ensuring Transparency in Prior Authorization Act” hinges on several key terms. "Prior authorization" refers to the process by which a healthcare provider must obtain approval from a patient's health plan or utilization review agent before a service or medication can be provided or covered. This process is central to the Act's regulatory scope, as it seeks to reform the criteria, timelines, and methods by which these approvals are granted or denied. The legislation specifically targets "utilization review agents," which are entities responsible for conducting the review of healthcare services to determine medical necessity and appropriateness of care. These agents are subject to the Act's new requirements for transparency, accountability, and the responsible use of technology.

Crucially, the Act introduces explicit regulations concerning "artificial intelligence-based algorithms." Although a precise, standalone definition of this term might be elaborated in accompanying regulations or guidance, the intent within LB 77 is clear: it refers to automated systems or computational processes that health plans or utilization review agents might employ to assist in, or make, prior authorization decisions. The legislation's prohibition on using such algorithms as the sole basis for denying, delaying, or modifying healthcare services underscores a legislative intent to ensure human oversight and clinical judgment in critical patient care determinations, mitigating potential risks associated with fully automated decision-making in healthcare. The Act also implicitly defines the scope of "biomarker testing" by mandating its coverage under specific conditions, indicating diagnostic or prognostic tests that measure biological molecules to assess health, disease, or treatment response.

Governance and Institutional Framework

The governance and institutional framework for the “Ensuring Transparency in Prior Authorization Act” is primarily centered around the Nebraska Department of Insurance (NDOI). The NDOI is vested with significant authority to oversee the implementation and enforcement of the Act's provisions. This includes the responsibility for developing and releasing standardized prior authorization forms, which became mandatory for fully insured health plans starting January 1, 2026. The department also provides guidance and ensures compliance from utilization review agents and health insurance companies operating within the state. The NDOI's role extends to monitoring the practices of these entities, particularly concerning their adherence to the new transparency requirements, review timelines, and the appropriate use of artificial intelligence in their processes.

Beyond its regulatory and oversight functions, the NDOI is empowered to conduct audits of utilization review agents' automated utilization management systems. This auditing capability is critical for ensuring that any AI-based algorithms used in prior authorization decisions comply with the Act's mandates, especially the prohibition against AI being the sole basis for denial. The department has the flexibility to contract with third-party entities to perform such audits, demonstrating a commitment to thorough and expert evaluation of these complex systems. This institutional framework ensures a robust mechanism for accountability, allowing the state to adapt to evolving technological advancements in healthcare while safeguarding patient interests and promoting fair administrative practices. The collaborative spirit among healthcare associations and insurers during the bill's development also suggests an ongoing, multi-stakeholder approach to its effective governance.

Key Focus Areas

The “Ensuring Transparency in Prior Authorization Act” concentrates on several critical areas to reform healthcare prior authorization. A primary focus is transparency and disclosure, requiring utilization review agents to make their prior authorization criteria publicly accessible on their websites. Furthermore, the Act mandates that providers receive at least 60 to 90 days' notice before any new prior authorization requirements or electronic methodologies are implemented. This ensures that healthcare professionals are well-informed and can adapt to changes without disrupting patient care. The legislation also requires utilization review agents to disclose if artificial intelligence-based algorithms are used in their review process, both to the NDOI, network providers, enrollees, and on their public websites, fostering a clearer understanding of the decision-making tools employed.

Another key area is streamlining processes and accountability. LB 77 introduces standardized prior authorization forms, effective January 1, 2026, aimed at reducing administrative burden and improving efficiency for providers and patients. It establishes clear and strict timelines for decision-making, particularly for urgent cases, with specific provisions for non-urgent requests to be addressed within seven days after all necessary information is obtained. The Act also enhances patient protection by prohibiting prior authorization requirements for emergency services, emergency ground transportation, and preventive services. Crucially, it ensures that adverse determinations are made by qualified physicians or clinical peers, and appeals are reviewed by same/similar-specialty physicians, thereby embedding human clinical accountability into the process. The legislation also addresses risk management by explicitly prohibiting artificial intelligence from being the sole basis for denying, delaying, or modifying healthcare services, emphasizing that AI should serve as a tool to support, not replace, human judgment in critical medical decisions. This multifaceted approach aims to create a more equitable, efficient, and patient-centered prior authorization system.

Implementation Framework

The implementation framework for the “Ensuring Transparency in Prior Authorization Act” is structured around a phased approach, with key components rolling out at different stages to ensure a smooth transition for healthcare providers, insurers, and patients. A cornerstone of this framework is the development and mandatory adoption of standardized prior authorization forms. The Nebraska Department of Insurance (NDOI) was responsible for releasing these new forms for Healthcare Services, Drug Benefits, and Durable Medical Equipment, which became effective on January 1, 2026, for all fully insured plans in Nebraska. This standardization is designed to reduce administrative complexities, minimize confusion, and enhance efficiency across the healthcare ecosystem, replacing the previous system where insurance companies often had individual, disparate forms.

Furthermore, the Act encourages and, in some aspects, mandates the use of electronic prior authorization methodologies. Utilization review agents are required to provide notice to healthcare providers at least ninety days prior to implementing a prior authorization application programming interface (API) or other electronic prior authorization methodology. This proactive notification ensures that providers have ample time to integrate new electronic systems and processes into their workflows, thereby facilitating a more seamless and automated prior authorization experience. The NDOI's authority to audit automated utilization management systems, including those incorporating AI, forms a critical part of this implementation, ensuring that technological advancements are deployed responsibly and in compliance with the Act's patient protection and transparency mandates. This comprehensive framework aims to modernize prior authorization practices while maintaining robust oversight and accountability.

Monitoring and Evaluation

The “Ensuring Transparency in Prior Authorization Act” establishes clear mechanisms for monitoring and evaluating the compliance and effectiveness of its provisions, particularly concerning the use of artificial intelligence in healthcare decision-making. A central element of this oversight is the authority granted to the Nebraska Department of Insurance (NDOI) to audit utilization review agents' automated utilization management systems. This power allows the NDOI to scrutinize the algorithms and processes employed by insurers to ensure they adhere to the Act's requirements, especially the critical stipulation that AI-based algorithms cannot be the sole basis for denying, delaying, or modifying healthcare services. The ability to conduct such audits, and even to contract with third-party entities for this purpose, signifies a proactive approach to regulating the evolving landscape of AI in healthcare.

Beyond direct audits, the Act's emphasis on transparency and disclosure inherently facilitates monitoring. The requirement for utilization review agents to publicly disclose their prior authorization criteria and to notify providers of any changes ensures that there is a visible standard against which their practices can be measured. Similarly, the mandate for agents to disclose if AI is used in the utilization review process, both to the NDOI and to the public, creates an additional layer of transparency that allows for ongoing scrutiny by stakeholders. These disclosure requirements, coupled with the NDOI's auditing powers, form a robust framework designed to continuously assess whether the Act's objectives of streamlining processes, enhancing accountability, and protecting patient interests are being met effectively in practice.

Penalties, Liability, and Appeals

While the “Ensuring Transparency in Prior Authorization Act” outlines specific requirements and prohibitions, it also establishes a framework for addressing non-compliance and ensuring avenues for redress. A key provision related to accountability is the mandate that adverse prior authorization determinations must be made by a qualified physician (or a clinical peer for non-physician requests). This ensures that decisions impacting patient care are rooted in professional medical judgment rather than solely automated processes. Furthermore, the Act stipulates that appeals of such determinations must be reviewed by a physician with the same or similar specialty as the healthcare provider requesting the service, thereby ensuring expertise and fairness in the review process.

Although the provided search results do not detail specific monetary penalties or criminal liabilities within LB 77, the enforcement authority granted to the Nebraska Department of Insurance (NDOI) implies that non-compliance would lead to regulatory actions. The NDOI's power to audit utilization review agents' systems suggests that violations of the Act's provisions, particularly those related to the misuse of AI or failure to adhere to transparency and timeline requirements, could result in corrective actions, fines, or other administrative sanctions imposed by the department. The Act also prohibits utilization review agents from basing any incentive or penalty for a medical reviewer on the volume of denials issued or upheld, directly addressing a potential conflict of interest that could influence prior authorization decisions and implicitly creating a liability for agents who fail to adhere to this principle.

Relationship to Other Instruments

The “Ensuring Transparency in Prior Authorization Act” operates within and modifies the existing legal landscape governing healthcare and insurance in Nebraska. It is an amendment to existing insurance laws and related statutes, rather than an entirely standalone piece of legislation. By adopting this Act, the Nebraska Legislature has introduced new sections and revised others to integrate the comprehensive prior authorization reforms into the state's established legal framework. This approach ensures that the new requirements and prohibitions, particularly those concerning transparency, timelines, and the use of AI, are legally binding and enforceable within the broader regulatory environment of health insurance and Medicaid.

Specifically, the Act's provisions regarding prior authorization processes, utilization review, and the coverage of biomarker testing are designed to supersede or refine previous regulations in these areas. For instance, the introduction of standardized forms and specific review timelines directly impacts how health insurance companies and utilization review agents must operate, potentially altering existing contractual agreements or internal policies. While LB 77 is a state-level initiative, its implications are also viewed in the context of broader national discussions around AI regulation in healthcare. Its focus on prohibiting AI as the sole basis for denial aligns with growing concerns at federal and other state levels regarding the ethical deployment of AI in critical sectors. However, it's important to note that the new forms and many provisions of LB 77 apply specifically to fully insured health plans and do not affect self-insured or ERISA plans, which are typically governed by federal law, thus delineating its relationship with federal instruments.

National/Federal Alignment

The “Ensuring Transparency in Prior Authorization Act” (LB 77) represents a significant state-level initiative in Nebraska that, while specific to the state, aligns with and contributes to a broader national discourse on the regulation of artificial intelligence in healthcare. The Act's explicit prohibition against using AI as the sole basis for denying, delaying, or modifying health care services reflects a growing consensus among policymakers and healthcare stakeholders across the United States regarding the need for human oversight in critical AI-driven decisions. This stance is particularly relevant given the ongoing debate at the federal level, where some members of Congress have pushed for a 10-year ban on state-driven AI regulation to encourage a more uniform national approach. However, states like Nebraska continue to advance their own regulations, demonstrating a proactive response to the rapid integration of AI into healthcare systems.

It is crucial to understand the scope of LB 77 concerning federal regulations. The Act's provisions, including the standardized prior authorization forms and review timelines, primarily apply to fully insured health plans operating within Nebraska. This distinction is important because self-insured and ERISA (Employee Retirement Income Security Act) plans are generally regulated at the federal level and are not directly affected by state mandates like LB 77. Healthcare providers and insurers must therefore confirm plan types to determine which regulatory framework applies. Despite this limitation, Nebraska's LB 77 sets a precedent and provides a model for other states considering similar legislation, contributing to a patchwork of state-level AI regulations that may eventually inform or influence future federal policies. The Act's emphasis on transparency, accountability, and patient protection in the context of AI-assisted prior authorization reflects principles that are widely supported across various levels of government and healthcare advocacy groups nationally.

Implementation Timeline

Sources and References